Citius Pharmaceuticals, Inc. CTXR
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-7.45
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | — | — | — | $67.6M |
| 2024 | — | — | — | — | $74.1M |
| 2023 | — | -$32.5M | — | — | $91.4M |
| 2022 | $90,000 | -$33.6M | — | — | $103.4M |
| 2021 | $90,000 | -$23.1M | — | -$24.3M | $132.8M |
| 2020 | $90,000 | -$17.5M | — | -$16.9M | $33.7M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -7.45 (distress)
- Working capital / assets -0.13
- Retained earnings / assets -1.824
- EBIT / assets -0.294
- Equity / liabilities 1.265
Source: SEC EDGAR filings · CIK 0001506251 · as of 2025-09-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.